Chinook Therapeutics, Inc.(KDNY) Stock Research - Grey Stern Research

Chinook Therapeutics, Inc. (KDNY) Stock Analysis

$40.39 (0.22%)

KDNY Financial Performance


Use the table below to view Chinook Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2023

Metric Value Ranking among Peers
Price $40.39 -
52 Week Low $18.34 -
52 Week High $40.51 -
Market Cap $2.7 Billion 10/18
Gross Margin 57% 7/18
Profit Margin -100% 12/18
EBITDA margin -6934% 16/18
Q2 - 2023 Revenue $1.0 Million 6/18
Q2 - 2023 Earnings -$66.9 Million 11/18
Q2 - 2023 Free Cash Flow -$61.8 Million 11/18
Trailing 4 Quarters Revenue $3.3 Million 8/18
Trailing 4 Quarters Earnings -$244.9 Million 13/18
Quarterly Earnings Growth -78% 15/18
Annual Earnings Growth -85% 18/18
Quarterly Revenue Growth 0% 5/18
Annual Revenue Growth 0% 5/18
Cash On Hand $127.1 Million 10/18
Short Term Debt $4.3 Million 7/18
Long Term Debt $29.7 Million 8/18

Chinook Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Chinook Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/18
PS 808.88 5/18
PB 7.58 4/18
PC 21.30 9/18
Liabilities to Equity 0.37 4/18
ROA -0.50 15/18
ROE -0.69 15/18
Current Ratio 3.71 14/18
Quick Ratio 2.26 14/18
Long Term Debt to Equity 0.08 4/18
Debt to Equity 0.10 5/18
Burn Rate 1.84 14/18
Cash to Cap 0.05 10/18
CCR 0.92 8/18
EV to EBITDA -37.41 13/18
EV to Revenue 781.05 5/18

Company Details

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

CEO: Mr. Stephen Isaacs

Website: https://www.chinooktx.com

Address: 740 Heinz Ave Berkeley, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Chinook Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Chinook Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Kura Oncology, Inc. KURA $1.6 Billion
Ascendis Pharma A/S ASND $7.6 Billion
Crinetics Pharmaceuticals, Inc. CRNX $4.3 Billion
Revolution Medicines, Inc. RVMD $7.7 Billion
SpringWorks Therapeutics, Inc. SWTX $2.8 Billion
Pliant Therapeutics, Inc. PLRX $806.6 Million
Vaxcyte, Inc. PCVX $9.1 Billion
Avidity Biosciences, Inc. RNA $4.6 Billion
Cerevel Therapeutics Holdings, Inc. CERE $8.1 Billion
Viridian Therapeutics, Inc. VRDN $1.1 Billion
Travere Therapeutics, Inc. TVTX $752.9 Million
Nuvalent, Inc. NUVL $5.3 Billion
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
DICE Therapeutics, Inc. DICE $2.3 Billion
Theseus Pharmaceuticals, Inc. THRX $181.5 Million
Arcellx, Inc. ACLX $3.4 Billion
Ventyx Biosciences, Inc. VTYX $208.0 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
KDNY Income Statements
Quarter Year Revenue Earnings
Q2 2023 $ 1.0 Million -$66.9 Million
Q1 2023 $ 1.8 Million -$60.2 Million
Q4 2022 $ 512,000 -$61.8 Million
Q3 2022 $ 0 -$56.0 Million
Q2 2022 $ 0 -$37.6 Million
Q1 2022 $ 0 -$31.7 Million
Q4 2021 $ 375,375 $110.4 Million
Q3 2021 $ 4,000 -$30.7 Million

View All

KDNY Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2023 $127.1 Million $488.8 Million $34.0 Million $357.0 Million
Q1 2023 $118.5 Million $543.9 Million $38.3 Million $412.4 Million
Q4 2022 $115.4 Million $574.1 Million $39.4 Million $441.9 Million
Q3 2022 $126.1 Million $590.3 Million $40.6 Million $474.6 Million
Q2 2022 $145.9 Million $601.2 Million $41.9 Million $507.1 Million
Q1 2022 $103.5 Million $531.3 Million $43.0 Million $426.8 Million
Q4 2021 $181.7 Million $563.8 Million $44.0 Million $453.6 Million
Q3 2021 $108.5 Million $383.3 Million $45.0 Million $269.8 Million

View All

KDNY Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2023 -$61.8 Million -$619,000 $8.7 Million
Q1 2023 -$51.6 Million -$927,000 $3.1 Million
Q4 2022 -$37.5 Million -$683,000 -$10.6 Million
Q3 2022 -$25.7 Million -$369,000 -$19.9 Million
Q2 2022 -$30.8 Million -$227,000 $42.4 Million
Q1 2022 -$25.1 Million -$374,000 -$78.2 Million
Q4 2021 $0 $0 $0
Q3 2021 -$25.5 Million -$753,000 -$26.9 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions